Skip to main content
. 2015 Sep 28;112(41):12806–12811. doi: 10.1073/pnas.1509667112

Fig. 1.

Fig. 1.

Synthesis and in vitro characterization of Bs-F(ab)2. (A) Schematic representation of the synthesis of Bs-F(ab)2. (B) SDS/PAGE gel confirming the identity and purity of Bs-F(ab)2. (C) Confocal images of U87MG cells incubated with FITC-labeled Bs-F(ab)2, CET-Fab, TRC105-Fab, or Bs-F(ab)2 coincubated with an excess of either CET, TRC105, or both antibodies. (Scale bar, 20 μm.) (D) Competitive binding assay comparing the binding affinities of Bs-F(ab)2 (circles), CET-Fab (squares), and TRC105-Fab (triangles). IC50 values were markedly lower for Bs-F(ab)2 (4.53 ± 0.77 nM) compared with CET-Fab (393 ± 84 nM) and TRC105-Fab (850 ± 720 nM).